Drugs / Tasipimidine
Tasipimidine
also known as
ODM-105 · ODM-105 SULFATE · ODM-105 sulphate · ORM-19695 · Tasipimidina · TASIPIMIDINE SULFATE · Tessie
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06956495 | Aug 2023 → Sep 2025 | insomnia | Orion Corporation, Orion Pharma | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-05-12 | Orion Corporation, Orion Pharma | Regulatory Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs orionpharma.com ↗
ORION CORPORATION PRESS RELEASE 12 MAY 2026 at 10:30 EEST Orion Corporation today announced that on 6 May 2026 the U.S. Food and Drug Administration (FDA) has approved Tessie® (tasipimidine) oral solution for dogs. |
| 2025-09-30 | Orion Corporation, Orion Pharma | Results Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal orionpharma.com ↗
Orion Corporation today announced that its candidate ODM-105 (tasipimidine) did not meet the primary goal in the clinical Phase 2 UNITAS study for the treatment of patients with insomnia. |
| 2021-06-21 | Orion Corporation, Orion Pharma | Regulatory Orion Animal Health’s Tessie® (tasipimidine) receives positive CVMP opinion orionpharma.com ↗
The Committee for Medical Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) has recommended Tessie® (tasipimidine) for marketing authorisation in the European Union. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-12 | Orion Corporation, Orion Pharma | Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs orionpharma.com ↗ |
| 2025-09-30 | Orion Corporation, Orion Pharma | Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal orionpharma.com ↗ |
| 2021-06-21 | Orion Corporation, Orion Pharma | Orion Animal Health’s Tessie® (tasipimidine) receives positive CVMP opinion orionpharma.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tasipimidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06956495 ↗ |
| Known as | ODM-105 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594267 ↗ |
| Known as | ODM-105 SULFATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594267 ↗ |
| Known as | ODM-105 sulphate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594267 ↗ |
| Known as | ORM-19695 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594267 ↗ |
| Known as | Tasipimidina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594267 ↗ |
| Known as | TASIPIMIDINE SULFATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594267 ↗ |
| Known as | Tessie | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594267 ↗ |
| Modality | Small molecule | — CHEMBL4594267 ↗ |